Investigating the Impact of Alisertib Treatment on Advanced EGFR-Mutated Lung Cancer

Alisertib Study Highlights

Puma Biotechnology recently presented findings from a Phase I/Ib study on the use of Alisertib in treating advanced EGFR-mutated lung cancer. The study investigated the efficacy of Alisertib in improving patient outcomes.

Key Findings:

• Promising Results: Alisertib showed potential in treating advanced EGFR-mutated lung cancer.
• Implications: The findings suggest a new avenue for treatment in this specific patient population.

The presentation emphasized the importance of continued research in developing targeted therapies for lung cancer patients.